Phillipp D. Le Coutre

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

T D Kim, Delphine Réa, Michaela Schwarz et al. · Leukemia · 2013 · 233 citations

Hematological Malignancy, Cardiovascular Disease, Hematology +5

MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia

Francis J. Giles, Ronan Swords, Arnon Nagler et al. · Leukemia · 2012 · 65 citations

Bcr–abl Inhibitor, Tumor Biology, Hematological Malignancy +8

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

Timothy P. Hughes, Andreas Hochhaus, Hagop M. Kantarjian et al. · Haematologica · 2014 · 48 citations · Full text

Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year.

Richard A. Larson, Phillipp D. Le Coutre, Josy Reiffers et al. · Journal of Clinical Oncology · 2010 · 38 citations

Pharmacotherapy, Myeloid Neoplasia, Chronic Phase +16

Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up.

Jörge E. Cortes, Michael J. Mauro, Michael W. Deininger et al. · Journal of Clinical Oncology · 2018 · 15 citations

Hematological Malignancy, Chronic Myeloid Leukemia, Imatinib Arm +15